4D pharma to Participate in Ladenburg Thalmann Healthcare Conference
4D pharma plc (NASDAQ: LBPS) announced that CEO Duncan Peyton and CSO Alex Stevenson will present at the Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 2:30 PM ET. The presentation will include a corporate overview and a fireside chat. A webcast will be accessible in the 'Events' section of the company's website, with an archived replay available for 90 days. 4D pharma is a leader in developing Live Biotherapeutics, leveraging its proprietary MicroRx® platform to create single-strain bacterial therapies targeting various diseases, including cancer and asthma.
- None.
- None.
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that Duncan Peyton, Chief Executive Officer, and Alex Stevenson, Chief Scientific Officer, will present a corporate overview followed by a fireside chat at the virtual Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021, at 2:30pm ET (7:30pm BST).
A webcast of the presentation will be available via the ‘Events’ section of the 4D pharma website at www.4dpharmaplc.com. An archived replay of the webcast will be available for 90 days following the presentation.
About 4D pharma
4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005157/en/
FAQ
When will 4D pharma present at the Ladenburg Thalmann Healthcare Conference?
Who will represent 4D pharma at the conference?
How can I access the presentation from 4D pharma?
What is the focus of 4D pharma's Live Biotherapeutics?
What clinical programs does 4D pharma have underway?
